Eli Lilly had a strong quarter as the company went ahead expanding its new set of drugs worldwide and advancing its pipeline candidates in late-stage development while also building long-term opportunities through early-stage investments in technology and progress in early-stage programs. In the third quarter, the company's revenue grew 18% with improved volumes. Many of Eli Lilly’s pipeline candidates achieved significant milestones including FDA approval for Verzenio to be used for people with ....
11 Nov 2021
Eli Lilly & Company - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 11/21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Eli Lilly & Company - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 11/21
- Published:
11 Nov 2021 -
Author:
Ishan Majumdar -
Pages:
14
Eli Lilly had a strong quarter as the company went ahead expanding its new set of drugs worldwide and advancing its pipeline candidates in late-stage development while also building long-term opportunities through early-stage investments in technology and progress in early-stage programs. In the third quarter, the company's revenue grew 18% with improved volumes. Many of Eli Lilly’s pipeline candidates achieved significant milestones including FDA approval for Verzenio to be used for people with ....